APLS APELLIS PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended March 31, 2026, APELLIS PHARMACEUTICALS INC reported revenue of $268M (up 60.9% from a year earlier), net income of $18.7M and diluted EPS of $0.15; over the last four quarters revenue was $1.11B and net income $133M; for the fiscal year ended December 2025 revenue was $1.00B, up 28.5% on the year before.

APLS annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $1.00B, gross profit n/a, operating income $55.4M, net income $22.4M (margin 2.2%), EPS $0.20
• Fiscal year ended Dec 2024: revenue $781M, gross profit n/a, operating income −$165M, net income −$198M (margin -25.3%), EPS −$1.60
• Fiscal year ended Dec 2023: revenue $397M, gross profit n/a, operating income −$517M, net income −$529M (margin -133.3%), EPS −$4.45
• Fiscal year ended Dec 2022: revenue $75.4M, gross profit n/a, operating income −$595M, net income −$652M (margin -864.7%), EPS −$6.15
• Fiscal year ended Dec 2021: revenue $66.6M, gross profit n/a, operating income −$536M, net income −$746M (margin -1121.3%), EPS −$8.84

APLS quarterly revenue and earnings

• Quarter ended Mar 31, 2026: revenue $268M (up 60.9% year over year), net income $18.7M, EPS $0.15
• Quarter ended Dec 31, 2025 (from the annual report): revenue $200M (down 5.9% year over year), net income −$59.0M, EPS −$0.40
• Quarter ended Sep 30, 2025: revenue $459M (up 133.0% year over year), net income $216M, EPS $1.67
• Quarter ended Jun 30, 2025: revenue $178M (down 10.6% year over year), net income −$42.2M, EPS −$0.33
• Quarter ended Mar 31, 2025: revenue $167M (down 3.2% year over year), net income −$92.2M, EPS −$0.74
• Quarter ended Dec 31, 2024 (from the annual report): revenue $213M (up 45.2% year over year), net income −$36.4M, EPS −$0.30
• Quarter ended Sep 30, 2024: revenue $197M (up 78.3% year over year), net income −$57.4M, EPS −$0.46
• Quarter ended Jun 30, 2024: revenue $200M (up 110.3% year over year), net income −$37.7M, EPS −$0.30
• Quarter ended Mar 31, 2024: revenue $172M (up 284.3% year over year), net income −$66.4M, EPS −$0.54
• Quarter ended Dec 31, 2023 (from the annual report): revenue $146M (up 545.9% year over year), net income −$88.6M, EPS −$0.70
• Quarter ended Sep 30, 2023: revenue $110M (up 400.5% year over year), net income −$140M, EPS −$1.17
• Quarter ended Jun 30, 2023: revenue $95.0M (up 481.8% year over year), net income −$122M, EPS −$1.02
• Quarter ended Mar 31, 2023: revenue $44.8M (up 211.8% year over year), net income −$178M, EPS −$1.56
• Quarter ended Dec 31, 2022 (from the annual report): revenue $22.7M, net income −$166M, EPS −$1.52
• Quarter ended Sep 30, 2022: revenue $22.1M (up 290.4% year over year), net income −$191M, EPS −$1.75
• Quarter ended Jun 30, 2022: revenue $16.3M (up 2519.9% year over year), net income −$156M, EPS −$1.46
• Quarter ended Mar 31, 2022: revenue $14.4M, net income −$139M, EPS −$1.42
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$148M, EPS −$1.52
• Quarter ended Sep 30, 2021: revenue $5.65M, net income −$196M, EPS −$2.28
• Quarter ended Jun 30, 2021: revenue $623K, net income −$219M, EPS −$2.72

APLS cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $45.3M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$87.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$595M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$514M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$563M, share buybacks n/a

APLS balance sheet

• Mar 31, 2026: cash $405M, total assets $1.08B, total liabilities $668M, shareholders' equity $415M
• Dec 31, 2025: cash $466M, total assets $1.08B, total liabilities $705M, shareholders' equity $370M
• Sep 30, 2025: cash $479M, total assets $1.06B, total liabilities $658M, shareholders' equity $401M
• Jun 30, 2025: cash $370M, total assets $821M, total liabilities $665M, shareholders' equity $156M
• Mar 31, 2025: cash $358M, total assets $807M, total liabilities $643M, shareholders' equity $164M
• Dec 31, 2024: cash $411M, total assets $885M, total liabilities $657M, shareholders' equity $229M
• Sep 30, 2024: cash $397M, total assets $902M, total liabilities $665M, shareholders' equity $237M
• Jun 30, 2024: cash $360M, total assets $904M, total liabilities $640M, shareholders' equity $264M

What is APLS's revenue?

APELLIS PHARMACEUTICALS INC reported $1.11B of revenue over its last four quarters, through March 31, 2026.

Is APLS profitable?

Yes. APELLIS PHARMACEUTICALS INC earned $133M over the last four quarters.

What is APLS's EPS?

Diluted earnings per share over the last four quarters were $1.09; $0.15 in the latest quarter.

APLS ownership and insider trades · All stocks